JNJ-1493

N/A

Report date: 2026/03/19 17:15:14

Base Information

Drug NameJNJ-1493
Drug Alias NameJNJ-1493
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionB-lymphocyte antigen CD20 modulatorsT-cell-specific surface glycoprotein CD28 modulators
TargetsB-lymphocyte antigen CD20T-cell-specific surface glycoprotein CD28
Therapy Area/IndicationsHematologic NeoplasmsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesXencor Inc
China Registration ClassN/A

Develop Information

Active CompaniesJohnson & Johnson IncXencor Inc
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A